L1CAM and neuroblastoma: Moreover, in a more recent pre-clinical assessment, (Kunkele et al. (2017) tested the safety of targeting the CE7 epitope CD171 with CE7-CAR T cells and determined whether bioactive CAR-T cells may be generated from heavily pretreated NB patients with recurrent or refractory disease.